-
Within a month, 430 institutions intensively investigated this pharmaceutical company!
Time of Update: 2022-02-17
Specifically, there are four important directions worthy of attention, including: the growth of the in vitro diagnostic business will accelerate; the company will continue to support the new medical infrastructure on a global scale, continue to achieve breakthroughs in high-end hospitals and increase the penetration rate, and expand brand influence; orthopedics and Some IVD products have benefited from the influence of centralized procurement, DRGS and other policies in some regions, and the market coverage and share have been accelerated.
-
The prospect of innovative traditional Chinese medicine is still optimistic
Time of Update: 2022-02-17
In addition, Fangsheng Pharmaceutical also stated to the relevant media not long ago that it will continue to increase investment in the research and development of innovative traditional Chinese medicine drugs .
-
In 2022, the "cooperation tide" of pharmaceutical companies has begun to rise
Time of Update: 2022-02-17
On the 11th, Fosun Pharma and Insilico Medicine also announced a cooperation agreement to jointly promote the research and development of AI drugs for multiple targets worldwide.
-
The market of 100 billion traditional Chinese medicine formula granules is being highly concerned by institutions
Time of Update: 2022-02-17
In the interactive session, the agency paid attention to the company's views on the centralized procurement of traditional Chinese medicine formula granules, and the price increase arrangements for products .
-
This month, more than 100 Class 1 new drugs have been approved for clinical use!
Time of Update: 2022-02-17
On the 18th, Osaikang announced that the innovative drug ASKG712 injection independently developed by Suzhou Osaikang, a wholly-owned subsidiary, was approved by the State Food and Drug Administration to carry out clinical trials.
-
The innovation and development of the traditional Chinese medicine industry requires both "soft and hard"
Time of Update: 2022-02-17
At the same time, it also stated that it will accelerate the research and development of products in related fields in terms of traditional Chinese medicine innovation, and continuously improve the added value of products .
-
The tens of billions of dollars in the drug market adds another competitor
Time of Update: 2022-02-17
Data show that in 2020, the sales of terminal adalimumab in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 1 billion yuan, a year-on-year increase of 995.
-
Under the rapid development of the domestic biopharmaceutical industry, the demand for high-end pharmaceutical equipment will continue to grow
Time of Update: 2022-02-17
In general, under the rapid development of the domestic biopharmaceutical industry, pharmaceutical machine companies need to seize the opportunity to accelerate the promotion of the pharmaceutical equipment industry into a new round of upgrading by introducing advanced technologies, and continue to meet the needs of pharmaceutical companies.
-
Innovative biopharmaceutical enterprises are ushering in a capital feast!
Time of Update: 2022-02-17
On the same day, Aiwei Pharmaceutical, an innovative biotechnology company focusing on the field of ophthalmic treatment, announced the completion of US$25 million in Series A+ financing.
Recently, Sihuan Pharmaceutical also announced that its holding subsidiary Xuanzhu Bio has completed over 600 million yuan in Series B financing .
-
Domestic pharmaceutical companies set off a "financing fever", and the research and development of innovative drugs will enter a "golden period"
Time of Update: 2022-02-17
(referred to as "Ruijian Medicine"), which is committed to the development of chemically induced adult cell drugs, also recently announced the completion of nearly 100 million yuan in Series A + financing .
-
Blockbuster biological drugs are included in the collection!
Time of Update: 2022-02-16
Compared with the previous draft for comments, the scope of the Guangdong Alliance’s centralized procurement in the official document has been further expanded, covering 276 chemicals and therapeutic biological products in the National Medical Insurance Drug Catalog with high consumption and high purchase amount, including human blood.
-
From the future planning of pharmaceutical machine enterprises, see the development trend of the industry!
Time of Update: 2022-02-16
On the whole, the author believes that increasing the international layout and developing high-end and intelligent pharmaceutical equipment has become the main development direction of most pharmaceutical equipment companies in 2022 .
-
These 10 medicines are the best sellers!
Time of Update: 2022-02-16
Judging from the supply of selected drugs in Henan Province's 2021 national centralized procurement, the variety with a supply rate of 100% is emtricitabine/tenofovir oral normal-release dosage form .
-
Chenxin Pharmaceutical's Levofloxacin Tablets obtained the drug registration certificate
Time of Update: 2022-02-16
Levofloxacin Tablets has strong antibacterial effect, broad antibacterial spectrum, and has a positive antibacterial effect.
-
In 2022, the pharmaceutical industry has begun to usher in a wave of drug withdrawals
Time of Update: 2022-02-16
The author was informed that, in addition to the removal of 113 drug product regulations from the Internet, on January 6, the Shanxi Provincial Center for Pharmaceutical and Equipment Bidding and Purchasing also issued the "Notice on Publicizing Some Enterprises' Application for Revocation of the Platform for Online Purchase Qualifications" .
-
Nomitoxantrone liposome in CSPC was approved for marketing, and Kunuoji's new traditional Chinese medicine icariin soft capsule was finally approved
Time of Update: 2022-02-16
According to the information pending for the approval of the Food and Drug Administration, CSPC's mitoxantrone liposome has been approved for marketing .
The approved indication of CSPC's liposome formulation is for the treatment of relapsed or refractory peripheral T-cell lymphoma .
-
AbbVie, AZ, Pfizer and other giants are under pressure: forging future competitiveness, where is the bet?
Time of Update: 2022-02-16
In fact, in the past two years, safety issues have emerged one after another with JAK inhibitors: in December 2021, in addition to AbbVie's Rinvoq, Pfizer's Xeljanz and Eli Lilly's Olumiant are also required to use new safety warnings and restrictions label .
-
The 2021 performance forecast of listed companies in the pharmaceutical equipment industry is sorted out
Time of Update: 2022-02-16
20% On January 17, Chutian Technology announced the 2021 annual performance forecast, the company expects the net profit attributable to shareholders of listed companies in 20215 100 million yuan – 600 million yuan, an increase of 149.
-
The seventh batch of centralized drug procurement work was launched, and the competition pattern of 58 varieties was opened
Time of Update: 2022-02-16
According to the "Notice on Submitting the Purchase Data Related to the Scope of the Seventh Batch of Nationally-Organized Centralized Drug Procurement" issued by the State-organized Drug Joint Procurement Office, which has been widely circulated in the industry recently, the seventh batch of centralized drug procurement has officially started, involving a total of 58 drugs.
-
Under the catalyst of favorable policies, the Chinese medicine track is ushering in a broader space for development
Time of Update: 2022-02-16
In recent years, under the background that the national policy strongly encourages and supports the development of traditional Chinese medicine, as well as the accelerated aging process of the population and the vigorous development of the health service industry, people's demand for the traditional Chinese medicine industry is becoming more and more vigorous .
